BFAI
BFAI, also known as 5,6-benzofuranyl-2-aminoindane, is a drug of the 2-aminoindane family that acts as a serotonin releasing agent and may produce entactogenic effects in humans, which may be useful for psychotherapeutic applications. It is closely related to MDAI but with the benzodioxole ring system replaced by benzofuran. The drug was patented by Matthew Baggott and Tactogen in 2022.